The company's transition from self-restraint to medication f...
The company's transition from self-restraint to medication for weight loss is seen as a necessary evolution, but the competitive landscape and supply constraints for GLP-1 drugs could pose challenges. As Oprah exits the stock, investors are advised to exercise caution.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000002815af1d5748f3.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment